4 Results

People

  1. Argyropoulos
    Argyropoulos
  2. Baslan
    Baslan
  3. Bewersdorf
    Bewersdorf
  4. Chung
    Chung
  5. Ciardiello
    Ciardiello
  6. Derkach
    Derkach
  7. Giralt
    Giralt
  8. Goldberg
    Goldberg
  9. Gonen
    Gonen
  10. Hassoun
    Hassoun

Groups

  1. Center for Hematologic Malignancies (4)
  2. Department of Medicine (4)
  3. Hematologic Malignancies, Division of (4)
  4. Graduate Medical Education (3)
  5. Sloan Kettering Institute Postdocs (3)
  6. Adult Leukemia (2)
  7. Biostatistics Service (2)
  8. Epidemiology and Biostatistics (2)
  9. GME, Medicine (2)
  10. Bone Marrow Transplant (1)
  1. "controlled study"
  2. "Hematologic Malignancies, Division of"
  3. "Blood Cancer Journal"
Formats
  1. Journal Article (2)
  2. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (4)
  2. Department of Medicine (4)
  3. Hematologic Malignancies, Division of (4)
  4. Graduate Medical Education (3)
  5. Sloan Kettering Institute Postdocs (3)
  6. Adult Leukemia (2)

More Groups

People
  1. Aaron Goldberg (1)
  2. Alexander Lesokhin (1)
  3. Amanda Ciardiello (1)
  4. Andriy Derkach (1)
  5. Carl Landgren (1)
  6. Carlyn Rose Tan (1)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2020 (1)
Publications
  1. Blood Cancer Journal (4)
Publishers
  1. Nature Publishing Group (4)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
    Research Letter

    Badar, T.; Nanaa, A.; Atallah, E.; Shallis, R. M.; Guilherme, S. D. C. C.; Goldberg, A. D.; Saliba, A. N.; Patel, A.; Bewersdorf, J. P.; DuVall, A. S.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
    Research Letter

    Rapaport, F.; Seier, K.; Neelamraju, Y.; Hassane, D.; Baslan, T.; Gildea, D. T.; Haddox, S.; Lee, T.; Murdock, H. M.; Sheridan, C.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
    Journal Article

    Munshi, M.; Liu, X.; Chen, J. G.; Xu, L.; Tsakmaklis, N.; Demos, M. G.; Kofides, A.; Guerrera, M. L.; Jimenez, C.; Chan, G. G.; more...
    Blood Cancer Journal (2020)

    Fulltext@MSK | Save